Medical Condition News

RSS

Study: HIV-positive head and neck cancer patients respond well to radiation therapy treatments

HIV-positive head and neck cancer patients respond well to radiation therapy treatments and experience similar toxicity rates as non-HIV-positive patients, despite prior reports to the contrary, according to a study in the January issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology.

19 Jan 2011

Salk Institute uncovers presenilin's productive side

Mutant presenilin is infamous for its role in the most aggressive form of Alzheimer's disease-early-onset familial Alzheimer's-which can strike people as early as their 30s. In their latest study, researchers at the Salk Institute uncovered presenilin's productive side: It helps embryonic motor neurons navigate the maze of chemical cues that pull, push and hem them in on their way to their proper targets.

19 Jan 2011

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

Novo Nordisk's new insulin pen for children receives 2010 GOOD DESIGN Award

A 2010 GOOD DESIGN Award has been awarded to Novo Nordisk for NovoPen Echo, the latest innovation in pen development - designed specifically with the needs of children in mind. Judging is made based on product design which is new, visionary and innovative and that may enrich people's lives.

From Novo Nordisk 19 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

Pisgah to scale-up patent-pending form of hydrocodone

As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.

19 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.

19 Jan 2011

Transplant surgeons routinely use fewer organs from high-risk donors

As a response to a 2007 episode in which four patients in Chicago were transplanted with organs from a single donor unknowingly infected with HIV — the only such episode in 20 years — one-third of transplant surgeons in the United States "overreacted" and began routinely using fewer organs from high-risk donors, new research from Johns Hopkins finds.

19 Jan 2011

Three-stage approach to fMRI could improve detection of neural activity

Over the last few years, researchers have used a type of brain scanning, known as functional magnetic resonance imaging fMRI, to help them map changes in blood flow in the brain and to correlate this with thoughts and behavior. A new way to analyze fMRI data, which could improve is reported in the International Journal of Computational Biology and Drug Design.

19 Jan 2011

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

Case Western Reserve University School of Medicine and Athersys, Inc. announced a joint scientific study on spinal cord injury will be published today in the January issue of The Journal of Neuroscience.

19 Jan 2011

Privatization of alcohol sales results in more alcohol-related death

Alcohol industry watchdog Marin Institute joined with Canadian and American researchers today to call attention to disturbing findings in a new study that should put the debate over privatizing alcohol sales in U.S. control states to rest once and for all.

19 Jan 2011

Study demonstrates role of alpha-synuclein cell-to-cell transfer in Parkinson's disease pathogenesis

The misfolding of abnormal proteins in brain cells is a key element in Parkinson's disease development. A recent study suggests that the sick proteins slowly move between cells, eventually triggering the destruction of the new host cell. The discovery could potentially lead to new therapeutic strategies for neurodegenerative diseases aimed at blocking the spread of protein misfolding throughout the brain.

19 Jan 2011

Europe's leading oncology organisations receive €12 million grant to streamline cross border research

Europe's leading oncology organisations are combining forces in the global fight against cancer. The project, EurocanPlatform, has received €12 million from the European Union to streamline cross border research. The project will find moreeffective ways to ensure the prevention, early discovery and treatment of different forms of cancer.

19 Jan 2011

Only half of adolescents affected with severely impairing mental disorders receive treatment

A recent study by Merikangas and colleagues published in the January 2011 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) shows that only half of adolescents that are affected with severely impairing mental disorders ever receive treatment for their disorders.

19 Jan 2011

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

UNC scientists who study how cells repair damage from environmental factors like sunlight and cigarette smoke have discovered how a "chaperone" enzyme plays a key role in cells' ability to tolerate the DNA damage that leads to cancer and other diseases.

19 Jan 2011

Concomitant physical symptoms in patients with depression and anxiety associated with poorer prognosis

This study, published in the last 2010 issue of Psychotherapy and Psychosomatics, indicate that concomitant physical symptoms in patients with depression and anxiety are associated with a poorer prognosis of symptoms of depression and anxiety and that it might prove worthwhile to pay attention to the role of multiple physical symptoms in the process of tailoring interventions to meet the needs of depressed and anxious patients in primary care.

19 Jan 2011

MD Anderson experts create plan to guide women on healthy behaviors

"A woman's life changes at every decade and so does her body," says Therese Bevers, M.D., medical director of MD Anderson's Cancer Prevention Center. "And, just as a woman sets personal and work-related milestones, she also should set health goals for every stage of life."

19 Jan 2011

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

19 Jan 2011

Medical Condition News

Study: HIV-positive head and neck cancer patients respond well to radiation therapy treatments

Salk Institute uncovers presenilin's productive side

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Novo Nordisk's new insulin pen for children receives 2010 GOOD DESIGN Award

Theraclone, Pfizer enter multi-year research and development collaboration

Pisgah to scale-up patent-pending form of hydrocodone

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

National Jewish Health issued method patent for desensitizing B cells

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Transplant surgeons routinely use fewer organs from high-risk donors

Three-stage approach to fMRI could improve detection of neural activity

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

Privatization of alcohol sales results in more alcohol-related death

Study demonstrates role of alpha-synuclein cell-to-cell transfer in Parkinson's disease pathogenesis

Europe's leading oncology organisations receive €12 million grant to streamline cross border research

Only half of adolescents affected with severely impairing mental disorders receive treatment

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

Concomitant physical symptoms in patients with depression and anxiety associated with poorer prognosis

MD Anderson experts create plan to guide women on healthy behaviors

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Latest News